TMPRSS2 and prostate cancer: The Mi-Prostate score combines PCA3 and TMPRSS2:ERG fusion with the multivariable Prostate Cancer Prevention Trial risk calculator (PCPT) for prediction of PCa (AUC = 0.762) and high-risk PCa (AUC = 0.779) which is comparable to our ProCUrE assay in the training cohort (AUC = 0.795 for benign vs high-risk PCa, Fig. 2) [30] Additionally, we demonstrated that ProCUrE, when combined with PCPT, has even greater AUCs for diagnosis (0.817) and prognostication (0.822) of PCa than the Mi-Prostate score.